Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Warning Shots: CureVac Sues BioNTech Over COVID Vax Patents

Pharma giants CureVac are suing Pfizer’s vaccine partner BioNTech over the development of the vaccine credited with saving the world from COVID19.

Zenger

Thinking of mixing and matching COVID-19 vaccine booster shots? There doesn't seem to be much point

Most people will have the Moderna or the Pfizer vaccine for their fourth dose. But the Doherty Institute's head of vaccine and immunisation research says there's practically no difference between them.

ABC News

From analysis to the latest developments in health,
read the most diverse news in one place.

The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Africa CDC signs with Pfizer for COVID pill for African countries

Pfizer will now supply the COVID-19 pill that is highly effective in preventing hospitalisations and deaths.

Al Jazeera

Australia’s booster doses explained: how to decide if you should get a fourth Covid vaccine and how long to wait

How long should I wait after a third dose? Should I wait for an Omicron-specific vaccine? Your questions answered

The Guardian - AU

COVID-19 boosters 'a matter of urgency' says Prime Minister as infections rise to highest level since February

Australia is expected to follow other parts of the world in expanding eligibility for a fourth COVID-19 vaccine dose to the wider population, with the Prime Minister saying the pandemic "isn't over" while encouraging eligible Australians to get their booster shots.

ABC News

Read news from The Economist, FT, and more,
with one subscription

Pfizer vaccines that target Omicron variant pass first step to approval in Australia

The TGA’s ‘provisional determination’ for two vaccines comes as BA.4 and BA.5 subvariants drive new wave of Covid cases

The Guardian - AU

What Are Whales Doing With Pfizer

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 11 strange trades.

Benzinga

How Pfizer won the pandemic, reaping outsize profit and influence

The grinding two-plus years of the pandemic have yielded outsize benefits for one company — Pfizer — making it both highly influential and hugely profitable as COVID-19 continues to infect tens of thousands of people and kill hundreds each day.

Tribune News Service

As Covid Cases Decline, is it Time to Drop Pfizer?

Leading drug maker Pfizer (PFE) experienced robust growth over the past year primarily based on the growing demand for its Covid vaccine. However, as Covid cases decline, will the company be able to maintain its growth trajectory? Let’s find out.

StockNews.com

What’s the UK’s booster policy ahead of a feared autumn Covid wave?

Tweaked vaccines to tackle Omicron are in trials as JCVI finalises advice for vulnerable groups

The Guardian - UK

FDA says COVID boosters for the fall must target newer omicron types

With immunity waning and the super-contagious omicron family of variants getting better at dodging protection, the Food and Drug Administration decided boosters intended for fall needed an update.

WEKU

Why Pfizer Stock Is Rising Today

Pfizer Inc (NYSE: PFE) shares are trading higher Thursday after the company and BioNTech SE (NASDAQ: BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government. SVB Leerink says that the new contract implies the price per Comirnaty dose is ~$30.50. Comirnaty U.S. pricing per dose has increased from $19.50 (2020 contracts), to $24 (+23%; 2021 contract), and now to ~$30.50 (+27%). The analysts…

Benzinga

Pfizer Seeks Complete Approval For Paxlovid For High Risk COVID-19 Patients

Pfizer Inc (NYSE:PFE) has submitted a new drug application to the FDA for the approval of Paxlovid for patients at high risk for progression to severe illness from COVID-19. Paxlovid is currently authorized for emergency use to treat mild-to-moderate COVID-19 in adults and pediatric patients at high risk for progression to severe COVID-19,…

Benzinga

Will Palantir, Pfizer And Oracle Stocks Continue Higher In This Trend?

Oracle Corporation (NYSE: ORCL), Pfizer Inc (NYSE: PFE) and Palantir Technologies Inc (NYSE: PLTR) were all trading near to fla

The Independent UK

Tweaked COVID boosters in US must target newer omicron types

U.S. regulators are telling COVID-19 vaccine makers to tweak any booster doses intended for fall so they protect against the newest omicron relatives

Get all your
news in one place.

100's of premium titles.
One news app.

Chicago Sun-Times

COVID vaccination reboot coming this fall to add tweaks for new coronavirus variants

The FDA will have to decide the exact recipe. But expect a combination shot that adds protection against omicron or some of its newer relatives to the original vaccine.

Benzinga

Check Out What Whales Are Doing With PFE

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 18 strange trades.

The Independent UK

Elmo, 3, joins youngest Americans in getting vaccinated

Elmo got a COVID-19 vaccine

Benzinga

Efficacy Of Pfizer's Paxlovid COVID Drug Crashes, According To New NIH-Funded Study

A new National Institutes of Health (NIH) funded study sheds new light on the waning effectiveness of Pfizer’s (NYSE: PFE) Paxlovid to prevent patient hospitalizations due to COVID.

Benzinga

Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'

The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news, announced Tuesday, June 28, could have a big impact on the share prices of vaccine makers.

Benzinga

Revive Therapeutics Data Access Plan Approved By The FDA; Partial Unblinded Data In Company Hands

Revive Therapeutics Ltd. (OTC: RVVTF) moved closer towards potential endpoint change in their Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine to treat COVID-19.

Tribune News Service

Fauci suffers COVID symptom rebound after course of Pfizer’s Paxlovid

Anthony Fauci, the chief medical adviser to President Joe Biden, suffered a rebound of COVID-19 symptoms after taking Pfizer Inc.’s antiviral Paxlovid.

1 … 44 45 46 47

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.